Publications by Elin H. Kure

75 publications found

Publications 2024

  1. Ankill J, Zhao Z, Tekpli X, Kure EH, Kristensen VN, Mathelier A, Fleischer T (2024)
    Integrative pan-cancer analysis reveals a common architecture of dysregulated transcriptional networks characterized by loss of enhancer methylation
    PLoS Comput Biol, 20 (11), e1012565
    DOI 10.1371/journal.pcbi.1012565, PubMed 39556603
  2. Stålberg SM, Silwal-Pandit L, Bastani NE, Nebdal DJH, Lingjærde OC, Skålhegg BS, Kure EH (2024)
    Preoperative profiles of plasma amino acids and derivatives distinguish periampullary cancer and benign disease
    BMC Cancer, 24 (1), 555
    DOI 10.1186/s12885-024-12320-8, PubMed 38702616

Publications 2022

  1. Callesen LB, Hamfjord J, Boysen AK, Pallisgaard N, Guren TK, Kure EH, Spindler KG (2022)
    Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis
    Br J Cancer, 127 (3), 500-513
    DOI 10.1038/s41416-022-01816-4, PubMed 35440666
  2. Khadse A, Haakensen VD, Silwal-Pandit L, Hamfjord J, Micke P, Botling J, Brustugun OT, Lingjærde OC, Helland Å, Kure EH (2022)
    Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
    Front Oncol, 12, 873532
    DOI 10.3389/fonc.2022.873532, PubMed 35574381
  3. Silwal-Pandit L, Stålberg SM, Henrik J. Johansson, Georgios Mermelekas, Lothe IMB, Skrede ML, Dalsgaard AM, Nebdal D, Helland, Lingjærde OC, Labori KJ, Skålhegg BS, Janne Lehtiö, Kure EH (2022)
    Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome
    Cancer Res Commun, 2 (6), 434-446
    DOI 10.1158/2767-9764.CRC-21-0100, PublikaID 411
  4. Silwal-Pandit L, Stålberg SM, Johansson HJ, Mermelekas G, Lothe IMB, Skrede ML, Dalsgaard AM, Nebdal DJH, Helland Å, Lingjærde OC, Labori KJ, Skålhegg BS, Lehtiö J, Kure EH (2022)
    Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome
    Cancer Res Commun, 2 (6), 434-446
    DOI 10.1158/2767-9764.CRC-21-0100, PubMed 36923555

Publications 2021

  1. Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, Lingjaerde OC, Tveit KM, Pallisgaard N, Spindler KG, Kure EH (2021)
    Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer
    Int J Cancer, 149 (6), 1385-1397
    DOI 10.1002/ijc.33672, PubMed 33961700
  2. Hamfjord J, Myklebust TÅ, Larsen IK, Kure EH, Glimelius B, Guren TK, Tveit KM, Guren MG (2021)
    Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study
    Cancer Epidemiol Biomarkers Prev, 31 (2), 342-351
    DOI 10.1158/1055-9965.EPI-21-0555, PubMed 34853022

Publications 2020

  1. Goleva-Fjellet S, Bjurholt AM, Kure EH, Larsen IK, Støren Ø, Sæbø M (2020)
    Distribution of allele frequencies for genes associated with physical activity and/or physical capacity in a homogenous Norwegian cohort- a cross-sectional study
    BMC Genet, 21 (1), 8
    DOI 10.1186/s12863-020-0813-1, PubMed 31973699
  2. Haakensen VD, Khadse A, Sandhu V, Halvorsen AR, Solberg SK, Jørgensen LH, Brustugun OT, Kure EH, Helland Å (2020)
    Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
    Int J Cancer, 147 (10), 2957-2966
    DOI 10.1002/ijc.33121, PubMed 32468587

Publications 2019

  1. Bowitz Lothe IM, Kleive D, Pomianowska E, Cvancarova M, Kure E, Dueland S, Gladhaug IP, Labori KJ (2019)
    Clinical relevance of pancreatobiliary and intestinal subtypes of ampullary and duodenal adenocarcinoma: Pattern of recurrence, chemotherapy, and survival after pancreatoduodenectomy
    Pancreatology, 19 (2), 316-324
    DOI 10.1016/j.pan.2019.01.019, PubMed 30713128
  2. Hamfjord J, Guren TK, Dajani O, Johansen JS, Glimelius B, Sorbye H, Pfeiffer P, Lingjærde OC, Tveit KM, Kure EH, Pallisgaard N, Spindler KG (2019)
    Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy
    Ann Oncol, 30 (7), 1088-1095
    DOI 10.1093/annonc/mdz139, PubMed 31046124
  3. Sandhu V, Labori KJ, Borgida A, Lungu I, Bartlett J, Hafezi-Bakhtiari S, Denroche RE, Jang GH, Pasternack D, Mbaabali F, Watson M, Wilson J, Kure EH, Gallinger S, Haibe-Kains B (2019)
    Meta-Analysis of 1,200 Transcriptomic Profiles Identifies a Prognostic Model for Pancreatic Ductal Adenocarcinoma
    JCO Clin Cancer Inform, 3, 1-16
    DOI 10.1200/CCI.18.00102, PubMed 31070984

Publications 2018

  1. Eide HA, Knudtsen IS, Sandhu V, Løndalen AM, Halvorsen AR, Abravan A, Kure EH, Bogsrud TV, Brustugun OT, Kyte JA, Malinen E, Helland Å (2018)
    Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
    Adv Radiat Oncol, 3 (2), 130-138
    DOI 10.1016/j.adro.2017.12.007, PubMed 29904737
  2. Halvorsen AR, Sandhu V, Sprauten M, Flote VG, Kure EH, Brustugun OT, Helland Å (2018)
    Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
    Acta Oncol, 57 (9), 1225-1231
    DOI 10.1080/0284186X.2018.1465585, PubMed 29683761
  3. Thomsen M, Skovlund E, Sorbye H, Bolstad N, Nustad KJ, Glimelius B, Pfeiffer P, Kure EH, Johansen JS, Tveit KM, Christoffersen T, Guren TK (2018)
    Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
    Br J Cancer, 118 (12), 1609-1616
    DOI 10.1038/s41416-018-0115-9, PubMed 29872151

Publications 2017

  1. Guren TK, Thomsen M, Kure EH, Sorbye H, Glimelius B, Pfeiffer P, Österlund P, Sigurdsson F, Lothe IMB, Dalsgaard AM, Skovlund E, Christoffersen T, Tveit KM (2017)
    Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
    Br J Cancer, 116 (10), 1271-1278
    DOI 10.1038/bjc.2017.93, PubMed 28399112
  2. Mezheyeuski A, Strell C, Hrynchyk I, Guren TK, Dragomir A, Doroshenko T, Pashkova O, Gorgun J, Ruksha K, Pfeiffer P, Kure EH, Sorbye H, Edler D, Martling A, Glimelius B, Östman A, Portyanko A (2017)
    Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer
    Virchows Arch, 472 (3), 395-405
    DOI 10.1007/s00428-017-2263-3, PubMed 29134439
  3. Thomsen M, Guren MG, Skovlund E, Glimelius B, Hjermstad MJ, Johansen JS, Kure E, Sorbye H, Pfeiffer P, Christoffersen T, Guren TK, Tveit KM (2017)
    Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status
    Eur J Cancer, 81, 26-35
    DOI 10.1016/j.ejca.2017.04.026, PubMed 28595137

Publications 2016

  1. Eide HA, Halvorsen AR, Sandhu V, Fåne A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, Helland Å (2016)
    Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
    Clin Transl Immunology, 5 (11), e109
    DOI 10.1038/cti.2016.65, PubMed 27990285
  2. Mezheyeuski A, Bradic Lindh M, Guren TK, Dragomir A, Pfeiffer P, Kure EH, Ikdahl T, Skovlund E, Corvigno S, Strell C, Pietras K, Ponten F, Mulder J, Qvortrup C, Portyanko A, Tveit KM, Glimelius B, Sorbye H, Östman A (2016)
    Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
    Oncotarget, 7 (27), 41948-41958
    DOI 10.18632/oncotarget.9632, PubMed 27248825
  3. Sandhu V, Wedge DC, Bowitz Lothe IM, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, Lingjærde OC, Børresen-Dale AL, Ikdahl T, Van Loo P, Nord S, Kure EH (2016)
    The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma
    Cancer Res, 76 (17), 5092-102
    DOI 10.1158/0008-5472.CAN-16-0658, PubMed 27488532
  4. Tarpgaard LS, Ørum-Madsen MS, Christensen IJ, Nordgaard C, Noer J, Guren TK, Glimelius B, Sorbye H, Ikdahl T, Kure EH, Tveit KM, Nielsen HJ, Pfeiffer P, Brünner N, Moreira JM (2016)
    TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer
    Oncotarget, 7 (37), 59441-59457
    DOI 10.18632/oncotarget.11118, PubMed 27509063
  5. Thomsen M, Kersten C, Sorbye H, Skovlund E, Glimelius B, Pfeiffer P, Johansen JS, Kure EH, Ikdahl T, Tveit KM, Christoffersen T, Guren TK (2016)
    Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
    Oncotarget, 7 (46), 75013-75022
    DOI 10.18632/oncotarget.12601, PubMed 27738330

Publications 2015

  1. Andersen V, Vogel LK, Kopp TI, Sæbø M, Nonboe AW, Hamfjord J, Kure EH, Vogel U (2015)
    High ABCC2 and low ABCG2 gene expression are early events in the colorectal adenoma-carcinoma sequence
    PLoS One, 10 (3), e0119255
    DOI 10.1371/journal.pone.0119255, PubMed 25793771
  2. Baekelandt BM, Hjermstad MJ, Nordby T, Fagerland MW, Kure EH, Heiberg T, Buanes T, Labori KJ (2015)
    Preoperative cognitive function predicts survival in patients with resectable pancreatic ductal adenocarcinoma
    HPB (Oxford), 18 (3), 247-54
    DOI 10.1016/j.hpb.2015.09.004, PubMed 27017164
  3. Bjaanæs MM, Fleischer T, Halvorsen AR, Daunay A, Busato F, Solberg S, Jørgensen L, Kure E, Edvardsen H, Børresen-Dale AL, Brustugun OT, Tost J, Kristensen V, Helland Å (2015)
    Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
    Mol Oncol, 10 (2), 330-43
    DOI 10.1016/j.molonc.2015.10.021, PubMed 26601720
  4. Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen TM, García-Santos G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen TL, Labori KJ, Lothe IM, Kure EH, Hernandez J, Doussot A, Ebbesen SH et al. (2015)
    Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver
    Nat Cell Biol, 17 (6), 816-26
    DOI 10.1038/ncb3169, PubMed 25985394
  5. Hamfjord J, Saldova R, Stöckmann H, Sandhu V, Bowitz Lothe IM, Buanes T, Lingjærde OC, Labori KJ, Rudd PM, Kure EH (2015)
    Serum N-Glycome Characterization in Patients with Resectable Periampullary Adenocarcinoma
    J Proteome Res, 14 (12), 5144-56
    DOI 10.1021/acs.jproteome.5b00395, PubMed 26515733
  6. Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K et al. (2015)
    Tumour exosome integrins determine organotropic metastasis
    Nature, 527 (7578), 329-35
    DOI 10.1038/nature15756, PubMed 26524530
  7. Kjersem JB, Thomsen M, Guren T, Hamfjord J, Carlsson G, Gustavsson B, Ikdahl T, Indrebø G, Pfeiffer P, Lingjærde O, Tveit KM, Wettergren Y, Kure EH (2015)
    AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin
    Pharmacogenomics J, 16 (3), 272-9
    DOI 10.1038/tpj.2015.54, PubMed 26261061
  8. Labori KJ, Katz MH, Tzeng CW, Bjørnbeth BA, Cvancarova M, Edwin B, Kure EH, Eide TJ, Dueland S, Buanes T, Gladhaug IP (2015)
    Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study
    Acta Oncol, 55 (3), 265-77
    DOI 10.3109/0284186X.2015.1068445, PubMed 26213211
  9. Sandhu V, Bowitz Lothe IM, Labori KJ, Skrede ML, Hamfjord J, Dalsgaard AM, Buanes T, Dube G, Kale MM, Sawant S, Kulkarni-Kale U, Børresen-Dale AL, Lingjærde OC, Kure EH (2015)
    Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma
    Mol Oncol, 10 (2), 303-16
    DOI 10.1016/j.molonc.2015.10.011, PubMed 26590090

Publications 2014

  1. Bjaanaes MM, Halvorsen AR, Solberg S, Jørgensen L, Dragani TA, Galvan A, Colombo F, Anderlini M, Pastorino U, Kure E, Børresen-Dale AL, Brustugun OT, Helland A (2014)
    Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
    Int J Cancer, 135 (8), 1812-21
    DOI 10.1002/ijc.28828, PubMed 24599520
  2. Kjersem JB, Skovlund E, Ikdahl T, Guren T, Kersten C, Dalsgaard AM, Yilmaz MK, Fokstuen T, Tveit KM, Kure EH (2014)
    FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
    BMC Cancer, 14, 340
    DOI 10.1186/1471-2407-14-340, PubMed 24884501
  3. Sandhu V, Bowitz Lothe IM, Labori KJ, Lingjærde OC, Buanes T, Dalsgaard AM, Skrede ML, Hamfjord J, Haaland T, Eide TJ, Børresen-Dale AL, Ikdahl T, Kure EH (2014)
    Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas
    Mol Oncol, 9 (4), 758-71
    DOI 10.1016/j.molonc.2014.12.002, PubMed 25579086
  4. Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, Kure EH, Sorbye H, Ikdahl T, Yilmaz M, Johansen JS, Tveit KM (2014)
    Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study
    PLoS One, 9 (2), e87746
    DOI 10.1371/journal.pone.0087746, PubMed 24498368
  5. Vogel LK, Sæbø M, Høyer H, Kopp TI, Vogel U, Godiksen S, Frenzel FB, Hamfjord J, Bowitz-Lothe IM, Johnson E, Kure EH, Andersen V (2014)
    Intestinal PTGS2 mRNA levels, PTGS2 gene polymorphisms, and colorectal carcinogenesis
    PLoS One, 9 (8), e105254
    DOI 10.1371/journal.pone.0105254, PubMed 25166592
  6. Wennerström AB, Lothe IM, Sandhu V, Kure EH, Myklebost O, Munthe E (2014)
    Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines
    PLoS One, 9 (8), e103873
    DOI 10.1371/journal.pone.0103873, PubMed 25148029

Publications 2013

  1. Andersen V, Vogel U, Godiksen S, Frenzel FB, Sæbø M, Hamfjord J, Kure E, Vogel LK (2013)
    Low ABCB1 gene expression is an early event in colorectal carcinogenesis
    PLoS One, 8 (8), e72119
    DOI 10.1371/journal.pone.0072119, PubMed 23977225
  2. Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH (2013)
    Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment
    Mol Oncol, 8 (1), 59-67
    DOI 10.1016/j.molonc.2013.09.001, PubMed 24119443
  3. Kure EH, Sæbø M, Stangeland AM, Hamfjord J, Hytterød S, Heggenes J, Lydersen E (2013)
    Molecular responses to toxicological stressors: profiling microRNAs in wild Atlantic salmon (Salmo salar) exposed to acidic aluminum-rich water
    Aquat Toxicol, 138-139, 98-104
    DOI 10.1016/j.aquatox.2013.04.004, PubMed 23728355

Publications 2012

  1. Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T, Kure EH (2012)
    Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing
    PLoS One, 7 (4), e34150
    DOI 10.1371/journal.pone.0034150, PubMed 22529906
  2. Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH (2012)
    Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
    BMC Cancer, 12, 534
    DOI 10.1186/1471-2407-12-534, PubMed 23167843
  3. Kure EH, Hamfjord J, Stangeland AM, Tveit KM, Ikdahl T (2012)
    KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem
    Expert Rev Mol Diagn, 12 (4), 327-8
    DOI 10.1586/erm.12.29, PubMed 22616697
  4. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T (2012)
    Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study
    J Clin Oncol, 30 (15), 1755-62
    DOI 10.1200/JCO.2011.38.0915, PubMed 22473155

Publications 2011

  1. Bornholdt J, Friis S, Godiksen S, Poulsen SS, Santoni-Rugiu E, Bisgaard HC, Lothe IM, Ikdahl T, Tveit KM, Johnson E, Kure EH, Vogel LK (2011)
    The level of claudin-7 is reduced as an early event in colorectal carcinogenesis
    BMC Cancer, 11, 65
    DOI 10.1186/1471-2407-11-65, PubMed 21310043
  2. Hamfjord J, Stangeland AM, Skrede ML, Tveit KM, Ikdahl T, Kure EH (2011)
    Wobble-enhanced ARMS method for detection of KRAS and BRAF mutations
    Diagn Mol Pathol, 20 (3), 158-65
    DOI 10.1097/PDM.0b013e31820b49e2, PubMed 21817902
  3. Marcos NT, Bennett EP, Gomes J, Magalhaes A, Gomes C, David L, Dar I, Jeanneau C, DeFrees S, Krustrup D, Vogel LK, Kure EH, Burchell J, Taylor-Papadimitriou J, Clausen H, Mandel U, Reis CA (2011)
    ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues
    Front Biosci (Elite Ed), 3 (4), 1443-55
    DOI 10.2741/e345, PubMed 21622148

Publications 2010

  1. Skjelbred CF, Svendsen M, Haugan V, Eek AK, Clausen KO, Kure EH, Tuimala JT, Svendsen MV, Norppa H, Hansteen IL (2010)
    Influence of GSTM1, GSTT1, GSTP1, NAT1, NAT2, EPHX1, MTR and MTHFR polymorphism on chromosomal aberration frequencies in human lymphocytes
    Carcinogenesis, 32 (3), 399-405
    DOI 10.1093/carcin/bgq246, PubMed 21097530

Publications 2009

  1. Andersen V, Agerstjerne L, Jensen D, Østergaard M, Saebø M, Hamfjord J, Kure E, Vogel U (2009)
    The multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is not associated with disease susceptibility in Norwegian patients with colorectal adenoma and colorectal cancer; a case control study
    BMC Med Genet, 10, 18
    DOI 10.1186/1471-2350-10-18, PubMed 19250544
  2. Hansteen IL, Clausen KO, Haugan V, Svendsen M, Svendsen MV, Eriksen JG, Skiaker R, Hauger E, Lågeide L, Vistnes AI, Kure EH (2009)
    Cytogenetic effects of exposure to 2.3 GHz radiofrequency radiation on human lymphocytes in vitro
    Anticancer Res, 29 (11), 4323-30
    PubMed 20032374
  3. Hansteen IL, Lågeide L, Clausen KO, Haugan V, Svendsen M, Eriksen JG, Skiaker R, Hauger E, Vistnes AI, Kure EH (2009)
    Cytogenetic effects of 18.0 and 16.5 GHz microwave radiation on human lymphocytes in vitro
    Anticancer Res, 29 (8), 2885-92
    PubMed 19661291
  4. Selzer-Plon J, Bornholdt J, Friis S, Bisgaard HC, Lothe IM, Tveit KM, Kure EH, Vogel U, Vogel LK (2009)
    Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis
    BMC Cancer, 9, 201
    DOI 10.1186/1471-2407-9-201, PubMed 19555470
  5. Skovbjerg H, Anthonsen D, Lothe IM, Tveit KM, Kure EH, Vogel LK (2009)
    Collagen mRNA levels changes during colorectal cancer carcinogenesis
    BMC Cancer, 9, 136
    DOI 10.1186/1471-2407-9-136, PubMed 19422682

Publications 2008

  1. Saebø M, Skjelbred CF, Brekke Li K, Bowitz Lothe IM, Hagen PC, Johnsen E, Tveit KM, Kure EH (2008)
    CYP1A2 164 A-->C polymorphism, cigarette smoking, consumption of well-done red meat and risk of developing colorectal adenomas and carcinomas
    Anticancer Res, 28 (4C), 2289-95
    PubMed 18751408

Publications 2007

  1. Lorentzen A, Vogel LK, Lewinsky RH, Saebø M, Skjelbred CF, Godiksen S, Hoff G, Tveit KM, Lothe IM, Ikdahl T, Kure EH, Mitchelmore C (2007)
    Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma
    BMC Cancer, 7, 192
    DOI 10.1186/1471-2407-7-192, PubMed 17935612
  2. Skjelbred CF, Saebø M, Hjartåker A, Grotmol T, Hansteen IL, Tveit KM, Hoff G, Kure EH (2007)
    Meat, vegetables and genetic polymorphisms and the risk of colorectal carcinomas and adenomas
    BMC Cancer, 7, 228
    DOI 10.1186/1471-2407-7-228, PubMed 18093316

Publications 2006

  1. Saebø M, Skjelbred CF, Nexø BA, Wallin H, Hansteen IL, Vogel U, Kure EH (2006)
    Increased mRNA expression levels of ERCC1, OGG1 and RAI in colorectal adenomas and carcinomas
    BMC Cancer, 6, 208
    DOI 10.1186/1471-2407-6-208, PubMed 16914027
  2. Sarebø M, Skjelbred CF, Breistein R, Lothe IM, Hagen PC, Bock G, Hansteen IL, Kure EH (2006)
    Association between cigarette smoking, APC mutations and the risk of developing sporadic colorectal adenomas and carcinomas
    BMC Cancer, 6, 71
    DOI 10.1186/1471-2407-6-71, PubMed 16545110
  3. Skjelbred CF, Saebø M, Nexø BA, Wallin H, Hansteen IL, Vogel U, Kure EH (2006)
    Effects of polymorphisms in ERCC1, ASE-1 and RAI on the risk of colorectal carcinomas and adenomas: a case control study
    BMC Cancer, 6, 175
    DOI 10.1186/1471-2407-6-175, PubMed 16817948
  4. Skjelbred CF, Saebø M, Wallin H, Nexø BA, Hagen PC, Lothe IM, Aase S, Johnson E, Hansteen IL, Vogel U, Kure EH (2006)
    Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control study
    BMC Cancer, 6, 67
    DOI 10.1186/1471-2407-6-67, PubMed 16542436
  5. Vogel LK, Saebø M, Skjelbred CF, Abell K, Pedersen ED, Vogel U, Kure EH (2006)
    The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals
    BMC Cancer, 6, 176
    DOI 10.1186/1471-2407-6-176, PubMed 16820046

Publications 2005

  1. Hansen R, Saebø M, Skjelbred CF, Nexø BA, Hagen PC, Bock G, Bowitz Lothe IM, Johnson E, Aase S, Hansteen IL, Vogel U, Kure EH (2005)
    GPX Pro198Leu and OGG1 Ser326Cys polymorphisms and risk of development of colorectal adenomas and colorectal cancer
    Cancer Lett, 229 (1), 85-91
    DOI 10.1016/j.canlet.2005.04.019, PubMed 15946795
  2. Stormorken AT, Bowitz-Lothe IM, Norèn T, Kure E, Aase S, Wijnen J, Apold J, Heimdal K, Møller P (2005)
    Immunohistochemistry identifies carriers of mismatch repair gene defects causing hereditary nonpolyposis colorectal cancer
    J Clin Oncol, 23 (21), 4705-12
    DOI 10.1200/JCO.2005.05.180, PubMed 16034045

Publications 2004

  1. Soucek P, Skjelbred CF, Svendsen M, Kristensen T, Kure EH, Kristensen VN (2004)
    Single-track sequencing for genotyping of multiple SNPs in the N-acetyltransferase 1 (NAT1) gene
    BMC Biotechnol, 4, 28
    DOI 10.1186/1472-6750-4-28, PubMed 15563733

Publications 2001

  1. Kristensen VN, Kure EH, Erikstein B, Harada N, Børresen-Dale A (2001)
    Genetic susceptibility and environmental estrogen-like compounds
    Mutat Res, 482 (1-2), 77-82
    DOI 10.1016/s0027-5107(01)00212-3, PubMed 11535251

Publications 2000

  1. Skaug V, Ryberg D, Kure EH, Arab MO, Stangeland L, Myking AO, Haugen A (2000)
    p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients
    Clin Cancer Res, 6 (3), 1031-7
    PubMed 10741731

Publications 1997

  1. Hollstein M, Bartsch H, Wesch H, Kure EH, Mustonen R, Mühlbauer KR, Spiethoff A, Wegener K, Wiethege T, Müller KM (1997)
    p53 gene mutation analysis in tumors of patients exposed to alpha-particles
    Carcinogenesis, 18 (3), 511-6
    DOI 10.1093/carcin/18.3.511, PubMed 9067550
  2. Kure EH, Andreassen A, Ovrebø S, Grzybowska E, Fiala Z, Strózyk M, Chorazy M, Haugen A (1997)
    Benzo(a)pyrene-albumin adducts in humans exposed to polycyclic aromatic hydrocarbons in an industrial area of Poland
    Occup Environ Med, 54 (9), 662-6
    DOI 10.1136/oem.54.9.662, PubMed 9423579

Publications 1996

  1. Andreassen A, Kure EH, Nielsen PS, Autrup H, Haugen A (1996)
    Comparative synchronous fluorescence spectrophotometry and 32P-postlabeling analysis of PAH-DNA adducts in human lung and the relationship to TP53 mutations
    Mutat Res, 368 (3-4), 275-82
    DOI 10.1016/s0165-1218(96)90069-5, PubMed 8692233
  2. Kure EH, Ryberg D, Hewer A, Phillips DH, Skaug V, Baera R, Haugen A (1996)
    p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels
    Carcinogenesis, 17 (10), 2201-5
    DOI 10.1093/carcin/17.10.2201, PubMed 8895489

Publications 1995

  1. Ovrebø S, Fjeldstad PE, Grzybowska E, Kure EH, Chorazy M, Haugen A (1995)
    Biological monitoring of polycyclic aromatic hydrocarbon exposure in a highly polluted area of Poland
    Environ Health Perspect, 103 (9), 838-43
    DOI 10.1289/ehp.103-1519226, PubMed 7498096

Publications 1994

  1. Ryberg D, Kure E, Lystad S, Skaug V, Stangeland L, Mercy I, Børresen AL, Haugen A (1994)
    p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer
    Cancer Res, 54 (6), 1551-5
    PubMed 8137262

Publications 1991

  1. Rappaport SM, Kure E, Petreas M, Ting D, Woodlee J (1991)
    A field method for measuring solvent vapors in exhaled air--application to styrene exposure
    Scand J Work Environ Health, 17 (3), 195-204
    DOI 10.5271/sjweh.1710, PubMed 2068559

 

 
Scroll to top